Global

  1. Global—English
  2. 中国—简体中文

Newsroom

Strive to Deliver Breakthroughs

HOME / Newsroom / Press Release
Press Release In the News Image Library Awards & Recognitions
  1. December 15, 2023

    Harbour BioMed's Wholly-owned Subsidiary Nona Biosciences Enters into a Global License Agreement with Pfizer for HBM9033, an MSLN-Targeted Antibody-Drug Conjugate (ADC)

    Harbour BioMed's Wholly-owned Subsidiary, Nona Biosciences, announced today that it has entered into an exclusive license agreement with Pfizer Inc. for th...

    View more
  2. August 28, 2023

    Harbour BioMed Announces 2023 Interim Results

    Cambridge, MA, Rotterdam, NL, Suzhou, CN - August 28, 2023   Harbour BioMed (“HBM”, or the "Company”; HKEX: 02142), a global ...

    View more
  3. August 28, 2023

    Harbour BioMed Announces US IND Clearance of Its First ADC Program HBM9033 in Solid Tumors

    Cambridge, MA, Rotterdam, NL, Suzhou, CN— August 28, 2023   Harbour BioMed (the“Company”, HKEX: 02142) announced that the U.S. Foo...

    View more
  4. August 08, 2023

    Harbour BioMed Appoints Dr. Albert R. Collinson as Independent Non-Executive Director

    Cambridge, MA, Rotterdam, NL, Suzhou, CN – August 8, 2023   Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical...

    View more
  5. July 13, 2023

    Harbour BioMed Announces 2023 Interim Results Positive Profit Alert with the Enhancement of Value Driven by Innovation

    Cambridge, MA, Rotterdam, NL, Suzhou, CN – July 13, 2023   Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical ...

    View more
  6. June 29, 2023

    Harbour BioMed Announces Biologics License Application Acceptance of Batoclimab for Treatment of Generalized Myasthenia Gravis by NMPA

    Cambridge, MA, Rotterdam, NL, Suzhou, CN – June 29, 2023   Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical ...

    View more
  7. June 05, 2023

    Harbour BioMed Announces First Patient Dosed in Phase I Study of First-in-Class Anti-B7H7 (HHLA2) Antibody HBM1020

    HBM1020 is a first-in-class therapeutic monoclonal antibody against B7H7/HHLA2 entering clinical development globally. HBM1020 was generated from Harbour ...

    View more
  8. May 26, 2023

    Harbour BioMed Reports Results of Phase Ib Clinical Trial of Porustobart in Combination of Toripalimab in Patients with Hepatocellular Carcinoma at ASCO 2023

      Porustobart in combination of toripalimab showed promising anti-tumor activity Porustobart in combination of toripalimab showed acceptable safet...

    View more
  9. April 14, 2023

    Harbour BioMed Announces Results of Phase Ib Clinical Trial of Porustobart in Combination with Toripalimab in Advanced High-Grade Neuroendocrine Neoplasms at AACR Annual Meeting

    Porustobart in combination with toripalimab showed promising anti-tumor activity in advanced high-grade neuroendocrine neoplasms (NENs) The ORR and DCR we...

    View more
  10. April 10, 2023

    Harbour BioMed Reports Full Year 2022 Financial Results

    CAMBRIDGE, Mass., SUZHOU, China and ROTTERDAM, Netherlands, April 3, 2023 /PRNewswire/ -- Harbour BioMed ("HBM" or...

    View more

Follow
Harbour BioMed
on WeChat

Copyright © 2025 Harbour BioMed. All Rights Reserved
沪公网安备31011502401396号 沪ICP备19015946号-1

FAMILY SITE

中文
ENG